Health
Sun Pharma Showcases Data Across its Dermatology & Immunology Portfolio at 2026 Winter Clinical Miami
Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or affiliated companies, "Sun Pharma") today announced the company will share 19 abstracts, including new clinical data, across its dermatology and immunology portfolio, at 2026 Winter Clinical Miami on February 27-March 1, 2026 in Aventura, Florida. The data presentations will include study results for several medications, including ILUMYA® (tildrakizumab-a
About this update from Sun Pharmaceutical Industries Limited
[{"type":"text","content":"New presentations for tildrakizumab-asmn explore real-world use in U.S. patients using Medicare ","length":100,"tagName":"p","attribs":{}},{"type":"text","content":"New data specific to patients with skin of color expands evidence supporting strong efficacy and safety for clascosterone cream 1%","length":130,"tagName":"p","attribs":{}},{"type":"text","content":"Robust set of 19 presentations across dermatology and immunology portfolio, including additional data for deuruxolitinib, highlight commitment to improved patient outcomes and scientific excellence","length":197,"tagName":"p","attribs":{}},{"type":"text","content":"MUMBAI, India and PRINCETON, N.J., Feb. 27, 2026 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or affiliated companies, "Sun Pharma") today announced the company will share 19 abstracts, including new clinical data, across its dermatology and immunology portfolio, at 2026 Winter Clinical Miami on February 27-March 1, 2026 in Aventura, Florida. The data presentations will include study results for several medications, including ILUMYA® (tildrakizumab-asmn), WINLEVI® (clascosterone cream 1%) and LEQSELVI™ (deuruxolitinib).","length":666,"tagName":"p"},{"type":"image","alt":"Sun Pharma Logo (PRNewsfoto/Sun Pharma)","displaySize":"","headline":null,"caption":"Sun Pharma Logo (PRNewsfoto/Sun Pharma)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/df5de24226c570ce4770ae1863771de9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.cfISXf9bI3Smy1Wj2vbaA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/df5de24226c570ce4770ae1863771de9","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/2320827/Sun_Pharma_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""The data we are sharing at Winter Clinical Miami reflect our patient-first focus on generating robust clinical and real‑world evidence for the treatment of alopecia areata, plaque psoriasis, and acne," said Ahmad Naim, MD, Senior Vice President and North American Chief Medical Officer, Sun Pharma. "Continued scientific evidence is essen...